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a  b  s  t  r  a  c  t
The  antifungal  posaconazole  (PCZ)  is  the most  advanced  candidate  for the  treatment  of Chagas  disease,
having  potent  anti-Trypanosoma  cruzi  activity  in  vitro and  in  animal  models  of  the  disease  as  well  as  an
excellent  safety  proﬁle  in  humans.  Amiodarone  (AMD)  is  the  antiarrhythmic  drug  most  frequently  used
for  the  symptomatic  treatment  of chronic  Chagas  disease  patients,  but it also  has  speciﬁc  anti-T.  cruzi
activity.  When  used  in  combination,  these  drugs  exhibit  potent  synergistic  activity  against  the  parasite.
In  the  present  work,  electron  microscopy  was  used  to  analyse  the  effects  of both  compounds,  acting  indi-
vidually  or  in  combination,  against  T.  cruzi.  The  50%  inhibitory  concentration  (IC50) against  epimastigote
and  amastigote  forms  was 25  nM  and  1.0 nM  for PCZ  and  8  M and  5.6  M for  AMD, respectively.  The
antiproliferative  synergism  of  the  drugs  (fractional  inhibitory  concentration  <  0.5)  was  conﬁrmed  and  the
ultrastructural  alterations  in  the  parasite  induced  by  them,  leading  to cell  death,  were  characterised  using
electron  microscopy.  These  alterations  include  intense  wrinkling  of  the protozoan  surface,  swelling  of  the
mitochondrion,  shedding  of  plasma  membrane  vesicles,  the  appearance  of vesicles  in  the  ﬂagellar  pocket,
alterations  in the  kinetoplast,  disorganisation  of  the  Golgi  complex,  accumulation  of lipid  inclusions  in
the  cytoplasm,  and  the  formation  of  autophagic  vacuoles,  the  latter  conﬁrmed  by  immunoﬂuorescence
microscopy.  These  ﬁndings  indicate  that  the  association  of PCZ  and  AMD  may  constitute  an  effective
anti-T.  cruzi  therapy  with  low  side  effects.
d the© 2012 Elsevier B.V. an
. Introduction
Chagas disease, recognised by the World Health Organization
WHO) as one of the world’s 13 most neglected tropical dis-
ases, continues to be a relevant social and economic problem in
any American countries. Caused by the protozoan Trypanosoma
ruzi, the overall illness prevalence is estimated to be ca. 16–18
illion cases [1,2]. Among those infected, 30–40% will subse-
uently develop the chronic form of the disease. Chronic Chagas
ardiomyopathy is the most serious outcome, leading to con-
uction abnormalities, cardiac failure and thromboembolism [3].
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io de Janeiro, Centro de Ciências da Saúde, Bloco G, Cidade Universitária, Ilha do
undão, Rio de Janeiro, CEP 21949-900, Brazil. Tel.: +55 21 2562 6580;
ax: +55 21 2260 2364.
E-mail  address: wsouza@biof.ufrj.br (W.  de Souza).
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Open acc International Society of Chemotherapy. 
The drugs currently available for the speciﬁc treatment of Cha-
gas disease (benznidazole and nifurtimox) have signiﬁcant activity
during the acute phase, with parasitological cure rates of up to
80%, but are signiﬁcantly less active in the prevalent chronic
stage. Furthermore, these drugs have frequent side effects such
as anorexia, vomiting, peripheral polyneuropathy and allergic der-
mopathy [4]. Thus, there is an urgent need for safer and more
effective drugs against this long-neglected disease. In this con-
text, anti-T. cruzi chemotherapy studies have been performed using
drugs from synthetic and natural sources, or commercially avail-
able drugs, originally developed for the treatment of other diseases
[5,6].
The antifungal posaconazole (PCZ) is currently the most
advanced candidate for the treatment of Chagas disease. The drug
targets the sterol biosynthesis pathway, inhibiting the protozoan’s
Open access under the Elsevier OA license.sterol C14-demethylase, a cytochrome P450-dependent enzyme
(CYP51), which results in potent antiparasitic effects both in vitro
and in animal models of Chagas disease [7–9]. PCZ also can erad-
icate amastigotes from cultured cardiomyocytes whilst allowing
ess under the Elsevier OA license.
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ull reassembly of the host cell’s cytoskeleton and contractile
pparatus [10]. Very recently, it was shown that PCZ cured an
mmunosuppressed patient with concomitant chronic Chagas dis-
ase and systemic lupus erythematosus who had previously failed
o achieve parasitological cure after benznidazole treatment [11].
CZ is already registered for the treatment of invasive fungal infec-
ions and is currently undergoing Phase II clinical trials to evaluate
ts efﬁcacy and safety for the speciﬁc treatment of chronic human
hagas disease [12].
On  the other hand, it has recently been shown that the
ntiarrhythmic drug amiodarone (AMD), frequently used for
he symptomatic treatment of chronic Chagas disease patients
ith cardiac compromise, also has selective anti-T. cruzi activ-
ty, acting by disruption of the parasite’s Ca2+ homeostasis and
nhibition of de novo ergosterol biosynthesis at the level of lanos-
erol synthesis. Furthermore, it has been shown that AMD  acts
ynergistically with PCZ against T. cruzi in vitro and in vivo
13].
Several drugs can activate programmed cell death (PCD)
echanisms such as autophagy and apoptosis [14–16]. In try-
anosomatids, PCD can have a biological role, maximising the
tness of the parasites’ populations and facilitating their adap-
ation to a digenetic life cycle [17]. Autophagy is the process of
atabolism of cellular components, such as the cytosol, organelles
nd protein aggregates, through their encapsulation by a double-
embrane structure known as the autophagosome. This process
an lead to death of the cell, either by actively degrading necessary
ellular components or by non-selective degradation of cellular
omponents [18].
In  view of the great potential for the use of PCZ and AMD
or the speciﬁc treatment of Chagas disease, we  decided to
eport, for the ﬁrst time, the cellular and ultrastructural aspects
f these compounds alone and in combination on the epi-
astigote and amastigote forms of T. cruzi. Use of electron
icroscopy allowed cellular structures signiﬁcantly affected by
he compounds to be identiﬁed. Based on the characteristic
orphological alterations observed in intracellular amastigotes
reated with both drugs as well as the localisation of LC3B
microtubule-associated protein light chain 3) in autophago-
omes, we conclude that treated parasites die by a process of
utophagy.
. Materials and methods
.1.  Drug solutionsStock  solutions of PCZ (0.01 mM)  and AMD  (1 mM)  were
repared in dimethyl sulphoxide (DMSO) (Merck, Darmstadt,
ermany), with the ﬁnal concentration of DMSO in the experiments
ever exceeding 0.05%.
ig. 1. Growth curve of Trypanosoma cruzi epimastigotes treated with (A) posaconazole 
erformed in triplicate and the bar represents the standard deviation. The arrow indicate
Control)  and LIT + 0.03% dimethyl sulphoxide (Ctl DMSO). Antimicrobial Agents 40 (2012) 61– 71
2.2. Parasites and cell culture
Trypanosoma  cruzi trypomastigotes (TcII - Y strain) [19] were
obtained from the supernatants of previously infected LLC-MK2
cells (ATCC CCL-7; American Type Culture Collection, Rockville,
MD) cultured in RPMI 1640 medium with garamycin (GIBCO, Grand
Island, NY) and 10% foetal bovine serum (FBS) (Cultilab, São Paulo,
Brazil) at 37 ◦C in a 5% CO2 atmosphere. Subconﬂuent cultures of
LLC-MK2 cells were infected with 5 × 106 trypomastigotes. Extra-
cellular parasites were removed after 2 h, the cells were washed
and these cultures were maintained in RPMI 1640 medium con-
taining 10% FBS until trypomastigotes emerged from the infected
cells (usually after 120 h).
Epimastigotes (TcII - Y strain) were cultivated in LIT medium
supplemented with 10% FBS [20] and were collected by centrifuga-
tion at 350 × g after 96 h of cultivation.
Resident peritoneal macrophages were obtained from Swiss CF1
mice. Cells were collected using Hank’s Balanced Salt Solution,
plated on round glass coverslips and allowed to adhere for 30 min
at 37 ◦C in a 5% CO2 atmosphere. Subsequently, non-adherent cells
were removed by washing and then 10% FBS–RPMI 1640 medium
was added. Cells were maintained in culture for 24 h at 37 ◦C in 5%
CO2 prior to their use in experiments.
2.3.  Effects of posaconazole and/or amiodarone on peritoneal
macrophages
The  viability of peritoneal macrophages treated with PCZ
(10–50 nM)  or AMD  (1–10 M)  was determined by Trypan blue
exclusion assay by incubating cells with 0.1% Trypan blue diluted
in distilled water for 5 min  at 37 ◦C in 5% CO2. After this period,
macrophages remained uncoloured, whilst dead cells were per-
meable to the blue solution and were thus stained blue. Drug
cytotoxicity was  estimated as the dose that reduced the number
of macrophages by 50%.
2.4.  Effects of posaconazole and/or amiodarone on Trypanosoma
cruzi
AMD  and PCZ were ﬁrst assayed on T. cruzi epimastigotes cul-
tured in LIT medium at 28 ◦C with strong agitation (120 rpm) and
starting with a cell density of 1 × 106/mL. Drugs were added after
24 h of growth in the range 0.03–50 nM PCZ for 168 h and 2–20 M
AMD for 144 h. Aliquots of the cultures were collected every 24 h
for counting in a Neubauer chamber. Controls consisted of LIT sup-
plemented with 10% FBS as well as LIT + 0.03% DMSO.To investigate the effect of the compounds on intracel-
lular amastigotes, peritoneal macrophages were seeded as
described above, subsequently washed with serum-free RPMI
1640 medium and incubated with T. cruzi trypomastigotes for
for 168 h and (B) amiodarone for 144 h, both incubated at 28 ◦C. Experiments were
s the time of addition of drug. Controls consisted of LIT supplemented with 10% FBS
rnal of Antimicrobial Agents 40 (2012) 61– 71 63
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Fig. 2. Effect of (A) posaconazole (PCZ) and (B) amiodarone (AMD) on intracellular
amastigotes  of Trypanosoma cruzi. Peritoneal macrophages were infected with try-
pomastigotes for 2 h, washed and then after 24 h were treated with 1–20 nM PCZ
or  4–20 M AMD for 96 h. The number of infected macrophages and the number
of  intracellular amastigotes were evaluated by counting a total of 500 cells in three
different experiments. Drug activity was estimated as the dose that reduced the
number of amastigotes per infected cell by 50% (IC50). Bars represent the standard
deviation.  (C) Isobologram describing the synergistic effects of PCZ and AMD  against
intracellular amastigotes of T. cruzi after 96 h of treatment. Dashed lines correspond
to the predicted positions of the experimental points for additive effects. A fractional
inhibitory concentration (FIC) of 0.42 was calculated according to Hallander et al.
[21]. Controls consisted of fresh 10% foetal bovine serum–RPMI 1640 medium.P. Veiga-Santos et al. / International Jou
 h. Non-internalised parasites were removed by washing and the
ells were incubated for 24 h at 37 ◦C to allow full internalisation
nd differentiation of trypomastigotes to amastigotes. Fresh
0% FBS–RPMI 1640 medium alone (control) or containing PCZ
1–20 nM)  or AMD (4–20 M)  was added to infected cells and
ncubated for 96 h at 37 ◦C. Infected cultures were ﬁxed in Bouin’s
olution and stained with Giemsa. Parasite infection was quan-
iﬁed under a Zeiss Axioplan light microscope (Carl Zeiss GmbH,
ena, Germany) using a 100 × lens. Association indexes [(mean
umber of parasites internalised per cell × percentage of infected
acrophages)/total number of macrophages] were determined
y counting a total of 500 cells and were used as a parameter
o calculate the intensity of infection in each condition in this
tudy. Drug activity was  calculated using SigmaPlot® v.10 (Systat
oftware Inc., San Jose, CA) estimating the dose that reduced the
umber of amastigotes per infected cell by 50% (IC50). Results are
xpressed as the mean of three independent experiments.
For evaluation of antiproliferative synergism against intracel-
ular amastigotes, fractional inhibitory concentrations (FICs) were
alculated as previously described [21]. A classical isobologram was
onstructed by plotting the concentrations of the drugs that alone
r in combination induced an IC50 of intracellular amastigotes, as
escribed above.
To  compare control and treated groups among all assays, paired
-tests were applied to results using a 95% conﬁdence interval
GraphPad Prism v.5.00 for Windows; GraphPad Software Inc., San
iego, CA).
.5.  Field-emission scanning electron microscopy (FESEM) and
onventional  scanning electron microscopy (SEM)
Trypanosoma cruzi epimastigotes were treated with 20 nM
r 40 nM PCZ for 120 h or with 8 M AMD for 72 h, both at
8 ◦C. Samples were subsequently ﬁxed in 2.5% glutaraldehyde
n 0.1 M phosphate buffer (pH 7.2) for 1 h, washed and adhered
o a specimen support coated with poly-l-lysine. Cells were then
ost-ﬁxed in 1% OsO4 and 0.8% potassium ferrocyanide in 0.1 M
odium cacodylate buffer (pH 7.2) at room temperature for 20 min,
ashed, dehydrated in ethanol and critical-point dried in CO2.
n addition, samples were ion-sputtered with a chrome layer
sing a Leica EM SCD500 high vacuum sputter coater (Leica
icrosystems, Nussloch, Germany) and were observed with a
EOL 6340 ﬁeld-emission scanning electron microscope (JEOL,
okyo, Japan) operating at 5.0 kV and 12 A or with a Zeiss DSM
62 scanning electron microscope (Carl Zeiss AG, Oberkochen,
ermany).
.6. Transmission electron microscopy (TEM)
For TEM, T. cruzi epimastigotes were treated with PCZ (20 nM
nd 40 nM)  or AMD  (8 M)  and were incubated for 120 h and 72 h,
espectively, at 28 ◦C. Macrophages infected for 24 h were treated
ith 1 nM PCZ or 5 M AMD  for 96 h. For the synergism assay,
nfected macrophages were treated with drug combinations, using
ICs of 0.42 and 0.46. Macrophage cultures were incubated for 96 h
t 37 ◦C. After the experimental procedure, samples were processed
s described by de Macedo-Silva et al. [22]. Ultrathin sections were
tained with uranyl acetate and lead citrate and were observed
ith a JEOL JEM-1200EX transmission electron microscope (JEOL,
kishima, Japan) operating at 80 kV.
.7.  Immunoﬂuorescence microscopy analysisFor immunoﬂuorescence assays, macrophages infected for
4 h were treated with PCZ and AMD  in combination (using
 FIC of 0.42) and were incubated for 96 h at 37 ◦C. Samples
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Fig. 3. Observation by ﬁeld emission scanning electron microscopy of Trypanosoma cruzi epimastigotes treated with posaconazole (PCZ) for 120 h. (A) Untreated parasite
showing an elongated body and an intact and smooth plasma membrane. (B) Epimastigotes treated with 20 nM PCZ showed marked disorganisation and intense wrinkling
of  the parasite membrane and an evident protuberance proximal to the kinetoplast (arrow). (C and D) Epimastigotes treated with 40 nM PCZ with severely affected plasma
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Dembrane and cell shape, contortion of the parasite body, disorganisation and form
ere ﬁxed in 4% formaldehyde (30 min), permeabilised with
.1% Saponin in 3% bovine serum albumin (BSA) in phosphate-
uffered saline (PBS) (pH 8.0) for 30 min  at room temperature and
locked with the same solution for 15 min. Cells were incubated
vernight with rabbit anti-LC3B antibody (Sigma Chemical Co.,
t Louis, MO)  at a dilution of 1:100, rinsed and incubated for
5 min  at room temperature with Alexa Fluor® 456-conjugated
oat anti-rabbit IgG (Molecular Probes, Carlsbad, CA) diluted
o 1:400. Subsequently, cells were rinsed in 3% BSA/PBS (pH
.0) and incubated with Hoechst dye (Molecular Probes) to
abel the nuclei. Coverslips were mounted and observed on a
eiss Axioplan ﬂuorescence microscope (Carl Zeiss GmbH, Jena,
ermany).
.8. Ethical guidelines
This  study was approved by the Ethics Committee of the Car-
os Chagas Filho, Biophysics Institute, Health Sciences Center, Rio
e Janeiro Federal University (permit no. IBCCF106). All animals
eceived humane care in compliance with the Principles of Labora-
ory Animal Care formulated by the National Society for Medical
esearch and the ‘Guide for the care and use of laboratory ani-
als’ prepared by the National Academy of Sciences (Washington,
C). of blebs in the ﬂagellar pocket, and a kinetoplast-proximal protuberance.
3. Results
3.1. Antiproliferative effects of amiodarone and posaconazole
alone and in combination against Trypanosoma cruzi
To  determine the effect of PCZ on epimastigote growth, parasites
were treated with increasing concentrations of the compound for
168 h at 28 ◦C, which led to dose-dependent growth inhibition, with
an IC50 of 25 nM after 168 h of incubation (Fig. 1A). PCZ also induced
a dose-dependent reduction both of the percentage of infected
macrophages and the mean number of intracellular amastigotes
per infected macrophage in cells previously infected for 24 h with
T. cruzi, with an IC50 of 1.0 nM after 96 h of drug treatment (Fig. 2A).
AMD also demonstrated a dose-dependent activity against epi-
mastigotes, with an IC50 value of 8 M after 144 h of treatment
(Fig. 1B). Against intracellular amastigotes, the IC50 was  5.6 M
after 96 h of treatment (Fig. 2B).
Treatment of peritoneal macrophages with 10 M AMD  or
50 nM PCZ did not affect viability of the mammalian cells, as
demonstrated by Trypan blue exclusion assay (data not shown).
The  effects of AMD  and PCZ acting in combination against
intracellular T. cruzi amastigotes were also investigated. When
compared with the IC50 values of the drugs when acting alone
(1.0 nM for PCZ and 5.6 M for AMD), the concentration of PCZ was
reduced to 0.25 nM in the presence of 1 M AMD  and to 0.2 nM in
P. Veiga-Santos et al. / International Journal of Antimicrobial Agents 40 (2012) 61– 71 65
Fig. 4. Transmission electron microscopy images of Trypanosoma cruzi epimastigotes treated with posaconazole (PCZ) for 120 h. (A) Untreated epimastigotes exhibiting
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rrow).  (C and D) Epimastigotes treated with 40 nM PCZ display vesicle formation (t
isternae (thick black arrow) and loss of kDNA compaction (white arrowhead). k, ki
he presence of 1.5 M AMD. The data led to a concave isobologram,
ith a FIC value of 0.42 (Fig. 2C).
.2. Morphological analysis of epimastigotes treated with
osaconazole and amiodarone
Epimastigote  forms of T. cruzi were treated with 20 nM and
0 nM PCZ for 120 h, processed and observed by FESEM. Untreated
pimastigotes revealed a typical elongated shape with a smooth
ell surface and intact ﬂagellar pocket region (Fig. 3A). Interestingly,
reatment with 20 nM PCZ caused plasma membrane disorganisa-
ion and intense wrinkling of the parasite surface. In addition, a
igniﬁcant protuberance was observed in the portion of the para-
ite body where the kinetoplast is located (Fig. 3B). Increased drug
oncentration (40 nM)  emphasised these alterations, also inducing
ontortion of the parasite body and formation of blebs in the ﬂag-
llar pocket (Fig. 3C and D). TEM analysis of epimastigotes treated
ith 20 nM PCZ revealed vacuoles similar to autophagosomes,
itochondrial swelling and formation of intramitochondrial mem-
ranes (Fig. 4B). A higher concentration (40 nM) induced the
ilatation of Golgi complex cisternae in the trans region, loss of
DNA compaction and the appearance of vesicles within the ﬂag-
llum (Fig. 4C and D).
Epimastigote  forms of T. cruzi were also treated with 8 M AMD
or 72 h, processed and observed by SEM (Fig. 5). After 48 h, treat-
ent induced pronounced rounding of parasites, disorganisation of
he plasma membrane (Fig. 5B and C) and detachment of the ﬂag-
llum from the protozoan cell body (Fig. 5D). Intense swelling was
oted after 72 h of treatment (Fig. 5E and F). TEM analysis of epi-
astigotes treated with 8 M AMD  for 24 h and 48 h revealed the
resence of myelin-like structures in the cytoplasm and swelling
n the mitochondrion–kinetoplast region (Fig. 6B and C). Aftermbranes within the mitochondria () and cytoplasmic autophagic vacuoles (white
ack arrow) in the ﬂagellar membrane, changes in the organisation of Golgi complex
last; m, mitochondrion; n, nucleus; g, Golgi complex; f, ﬂagellum.
72  h (Fig. 6D), swelling of the perinuclear space, disorganisation of
the kinetoplast structure, condensation of nuclear chromatin, the
presence of vesicles in the ﬂagellar pocket, and autophagosome
formation were observed. After 96 h, the cells were completely
destroyed (data not shown).
3.3.  Ultrastructural analysis of intracellular amastigotes treated
with  posaconazole and/or amiodarone by transmission electron
microscopy
Previously  infected macrophages containing T. cruzi amastigotes
were incubated with 1 nM PCZ or 5 M AMD  for 96 h, processed
and observed by TEM. Normal ultrastructure was observed in
untreated infected macrophages and parasites (Fig. 7A). In intra-
cellular amastigotes treated with PCZ, an accumulation of vesicles
in the cytoplasm and ﬂagellar pocket was observed as well and
shedding of intracellular content from the plasma membrane
(Fig. 7B and D). After 96 h of treatment with AMD  (Fig. 8), mem-
brane shedding (Fig. 8B), Golgi complex disorganisation (Fig. 8C),
accumulation of cytoplasmic lipid bodies, and vacuoles similar to
autophagosomes were observed (Fig. 8D).
As expected, intracellular amastigotes treated with PCZ plus
AMD exhibited a combination of the alterations described
above. No alterations were observed in amastigotes and infected
macrophages cultured in the absence of drugs (Fig. 7A). The com-
bination of PCZ plus AMD  at a FIC of 0.42 (Fig. 9B and C) and a FIC of
0.46 (Fig. 9D and F) for 96 h showed extreme accumulation of vesi-
cles and the appearance of vacuoles in the parasite’s cytoplasm.
The treatment also caused membrane shedding, the presence of
myelin-like structures and disruption of the amastigote plasma
membrane (Fig. 9E).
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Fig. 5. Morphological alterations in Trypanosoma cruzi epimastigotes treated with 8 M amiodarone for 72 h and visualised by scanning electron microscopy. (A) Control. (B
and  C) Epimastigotes treated for 48 h show a rounded appearance (arrow). (D) Flagellum detached from the protozoan cell body (*). (E and F) Epimastigotes treated for 72 h
exhibit  swollen membranes (arrowhead) and a rounded appearance.
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(.4. Programmed cell death by autophagy in intracellular
mastigotes treated with synergistic concentrations of
osaconazole and amiodarone
To  assess the mechanism of cell death in intracellular
mastigotes  treated with synergistic concentrations of PCZ and
MD, infected macrophages were analysed by immunoﬂu-
rescence microscopy using an anti-LC3B antibody typically
mployed to identify autophagic structures. Strong labelling of the
tructures was observed in parasites treated at a FIC value of 0.42
Fig. 10D–F). No labelling was observed in untreated amastigotes
Fig. 10A–C).4. Discussion
Recently, Benaim et al. [13] demonstrated that AMD, a well-
known antiarrhythmic agent, also possesses intrinsic activity
against T. cruzi in vitro and in vivo. In this study, we  conﬁrmed that
AMD has signiﬁcant activity against the proliferation of T. cruzi epi-
mastigote and amastigotes without affecting the viability of the
host cell. This activity results from a dual mechanism of action
against the parasite, disruption of Ca2+ homeostasis and blockage
of de novo ergosterol biosynthesis [13]. It should be noted that the
concentrations of PCZ and AMD  that eradicate amastigotes from
infected mammalian cells in vitro can be attained in the heart and
P. Veiga-Santos et al. / International Journal of Antimicrobial Agents 40 (2012) 61– 71 67
Fig. 6. Transmission electron microscopy images of Trypanosoma cruzi epimastigotes treated with 8 M amiodarone (AMD). (A) Untreated epimastigotes exhibit organelles
with normal morphology. (B) Epimastigotes treated with AMD for 24 h show myelin-like structures (arrowhead). (C) Epimastigotes treated with AMD  for 48 h exhibit swelling
in  the region of the kinetoplast (arrow). (D) Treatment for 72 h induced swelling of the perinuclear space (black arrowhead), disorganisation of kinetoplast structure (star),
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[he  presence of vesicles in the ﬂagellar pocket (arrow) and the formation of autopha
ocket; F, ﬂagellum; Bars: 200 nm.
ther internal organs at the recommended therapeutic doses of
hese drugs [23,24], indicating that these results are physiologically
elevant.
Ultrastructural analysis of epimastigotes treated with AMD
howed the presence of myelin-like structures in the cytoplasm
nd swelling in the mitochondrion–kinetoplast complex. These
ffects were previously observed in epimastigotes treated with
ther sterol biosynthesis inhibitors [25]. In addition, AMD  also
aused the appearance of large autophagosomes in the cytoplasm
nd swelling of the perinuclear space of these cells. A previous
tudy also found that Leishmania amazonensis promastigotes incu-
ated with AMD exhibited large autophagosomes and alterations in
he mitochondrion–kinetoplast complex [22]. In this case, AMD  led
o severe alterations of mitochondrial function, conﬁrmed by ﬂu-
rescence microscopy, causing parasite death. AMD  also disrupted
he epimastigotes’ surface, probably due to inhibition of ergosterol
iosynthesis.Intracellular amastigotes treated with AMD exhibited
utophagosomes, projections of the plasma membrane, disruption
f the Golgi complex and accumulation of lipid bodies. Lazardi et al.
26] previously described the presence of autophagic vacuoles ines (A). k, kinetoplast; m,  mitochondrion; n, nucleus; G, Golgi complex; fp, ﬂagellar
amastigotes  treated with other sterol biosynthesis inhibitors such
as ketoconazole and terbinaﬁne. Using AMD against intracellular
T. cruzi amastigotes, Adesse et al. [27] described alterations such as
mitochondrial swelling, reservosomes and kinetoplast disorgani-
sation after 144 h. The fact that these effects were not observed in
this study is likely due to the type of host cell used; Adesse et al.
[27] used murine cardiomyocytes, whereas the current study used
peritoneal macrophages.
New  results on the ultrastructural alterations caused in T. cruzi
by PCZ, a drug that interferes with ergosterol biosynthesis leading
to the accumulation of methylated sterol precursors that are known
to disrupt the packing of phospholipid bilayers, were also obtained.
In a previous study [9], it was shown that the activity of PCZ against
intracellular amastigotes was  at nanomolar to sub-nanomolar con-
centrations. Drastic alterations in the mitochondrion–kinetoplast
region,  such as swelling, abnormal membranes in the matrix and
loss of kDNA compaction, induced by this drug in epimastigotes
are typically associated with ergosterol depletion, mitochondrial
de-energisation and osmotic imbalance [26]. The appearance of
autophagosomes suggests cell death. The drug also caused disor-
ganisation of the Golgi complex cisternae and formation of vesicles
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Fig. 7. Transmission electron microscopy images of intracellular amastigotes of Trypanosoma cruzi treated with 1 nM posaconazole (PCZ) for 96 h. (A) Untreated intracellular
amastigote. (B) Parasites exhibit formation of vesicles in the cytoplasm (arrowhead). (C) Plasma membrane shedding (black arrow). (D) Numerous vesicles in the ﬂagellar
p , nucle
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s
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s
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o
ﬁocket (white arrow) following PCZ treatment. k, kinetoplast; m,  mitochondrion; n
n the ﬂagellum sheath. Other drugs that interfere with lipid
ynthesis, such as ketoconazole, lysophospholipid analogues and
aphthoimidazoles, cause similar alterations in the parasite, lead-
ng to complete cell disintegration [14,26].
Incubation of intracellular T. cruzi amastigotes with PCZ caused
ntense shedding of vesicles originating from the plasma mem-
rane. This alteration is probably due to changes in the chemical
omposition of the parasites’ membranes caused by sterol inhibi-
ion as well as destabilisation of membranes. The drug also led to
he formation of large vacuoles with vesicles in the ﬂagellar pocket
nd abnormal vacuolisation of the cytoplasm. As described by Doyle
t al. [28], bovine embryo skeletal muscle cells infected with T. cruzi
nd treated with PCZ also showed alterations in plasma membrane
rganisation. In addition, previous work demonstrated that treat-
ent of trypanosomatid parasites with AMD, azasterols and other
terol biosynthesis inhibitors, such as ketoconazole and terbinaﬁne,
nduced the appearance of membranous structures forming vac-
oles and vesicles in the ﬂagellar pocket [22,26,29].
According to Wagner and Ulrich-Merzenich [30], synergism
etween two drugs can be demonstrated when the effect pro-
uced by the compounds used in combination is higher than the
um of the effects of each compound used alone. The synergistic
ffects between AMD  and PCZ have been demonstrated previ-
usly against T. cruzi amastigotes [13]. Here we report for the
rst time the cellular and ultrastructural aspects of the synergismus; F, ﬂagellum.
action  mechanisms of PCZ and AMD  against T. cruzi. The synergis-
tic effect against the proliferation of amastigotes was conﬁrmed,
since the FIC observed was <0.5 (FIC = 0.42). We  investigated
for the ﬁrst time the cellular and subcellular alterations caused
by the drug combination using microscopy techniques such as
SEM, FESEM and TEM. This combination of drugs resulted in
autophagic death of the intracellular amastigote. Using the anti-
LC3B antibody, a speciﬁc marker for autophagosome formation,
robust staining was observed in treated intracellular amastig-
otes. This conclusion was also supported by the results obtained
by TEM, which also indicated the presence of a large num-
ber of autophagosomes in treated cells. The profound alterations
observed in the ultrastructure of amastigotes treated with both
PCZ and AMD  induced autophagic death without any effects on
the host cells. This combination may  constitute a very effective
anti-T. cruzi therapy, since PCZ is the most potent known agent
against Chagas disease, with an excellent safety proﬁle, whilst
AMD is the most frequently used antiarrhythmic drug in patients
with cardiac compromise. Both drugs in synergy could be effec-
tive in arresting parasite proliferation in the mammalian host at
doses lower than those required when used alone, reducing the
potential cost (PCZ) or toxic effects (AMD) involved. In addition,
both drugs are commercially available and safely used, becom-
ing strong candidates for the treatment of patients with Chagas
disease.
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Fig. 8. Transmission electron microscopy images of intracellular amastigotes of Trypanosoma cruzi treated with 5 M amiodarone (AMD) for 96 h. (A) Untreated intracellular
amastigotes. (B and D) Intracellular amastigotes treated with AMD display severe membrane shedding (black arrow) and alterations in Golgi complex (white arrowhead).
(C) Accumulation of lipid bodies (*). K, kinetoplast; M,  mitochondrion; N, nucleus; F, ﬂagellum; HC, host cell.
Fig. 9. Transmission electron microscopy images of intracellular amastigotes of Trypanosoma cruzi treated with synergistic concentrations using fractional inhibitory con-
centrations (FICs) of 0.42 and 0.46 for posaconazole (PCZ) plus amiodarone (AMD) for 96 h. (A) Untreated intracellular amastigote displays a kinetoplast (k), nucleus (n),
mitochondrion (m)  and ﬂagellum (f). (B and C) Parasite treated with 0.25 nM PCZ plus 1 M AMD  shows formation of vesicles (black arrowhead) and vacuoles (white arrow-
head) in the cytoplasm. (D and E) Parasite treated with 0.20 nM PCZ plus 1.5 M AMD  exhibits myelin-like structures (black arrow), membrane shedding (white arrow)
and disruption of the amastigote plasma membrane (). (F) Parasite treated with the same concentrations of AMD  and PCZ demonstrates vacuoles that resemble modiﬁed
reservosomes, with lipid inclusions (large white arrow).
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Fig. 10. Immunoﬂuorescence microscopy demonstrating labelling of structures when incubated in the presence of antibodies against LC3B (microtubule-associated protein
light  chain 3), a marker of autophagic cell death, in intracellular amastigotes treated with synergistic concentrations of posaconazole (PCZ) and amiodarone (AMD). (A–C)
Untreated infected macrophages after 96 h of incubation are not labelled. (D–F) Intracellular amastigotes treated with synergistic concentrations of PCZ and AMD  at a
fractional inhibitory concentration of 0.42 exhibit intense red labelling (arrowhead). Bar = 5 m.  (For interpretation of the references to colour in this ﬁgure legend, the reader
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